ResoTher Pharma initiates dosing in its Phase 2a clinical trial in myocardial infarction patients
ResoTher Pharma is pleased to announce that the first patient has been [...]
ResoTher Pharma: Improving Cardiovascular Outcomes
Please read our biography published in Life Sciences Review 'Company of the [...]
ResoTher Pharma receives a €2.5 million grant from the European Innovation Council
ResoTher Pharma, a biotech company focused on developing life-saving options for [...]
ResoTher Pharma appoints Anders Kronborg as Chief Executive Officer
Resother Pharma A/S (“ResoTher”) today announced the appointment of Anders Kronborg, as [...]
ResoTher Pharma appoints Dr. Markus Weissbach as Chief Medical Officer
ResoTher Pharma is pleased to announce the appointment of Dr. Markus Weissbach, [...]
Resother Pharma initiates First in Human studies with RTP-026
ResoTher Pharma today announced that the company has received approval to initiate [...]
ResoTher Pharma initiates dosing in its Phase 2a clinical trial in myocardial infarction patients
ResoTher Pharma is pleased to announce that the first patient [...]
ResoTher Pharma: Improving Cardiovascular Outcomes
Please read our biography published in Life Sciences Review 'Company [...]
ResoTher Pharma receives a €2.5 million grant from the European Innovation Council
ResoTher Pharma, a biotech company focused on developing life-saving [...]
ResoTher Pharma appoints Anders Kronborg as Chief Executive Officer
Resother Pharma A/S (“ResoTher”) today announced the appointment of Anders [...]
ResoTher Pharma appoints Dr. Markus Weissbach as Chief Medical Officer
ResoTher Pharma is pleased to announce the appointment of Dr. [...]
Resother Pharma initiates First in Human studies with RTP-026
ResoTher Pharma today announced that the company has received approval [...]
